Association of Far-Infrared Radiation Therapy and Ankle-Brachial Index of Patients on Hemodialysis with Peripheral Artery Occlusive Disease

August 13, 2017

Abstract

Background and Aim

The ankle-brachial index (ABI) is recognized to be a good marker for

atherosclerosis, and is useful in the diagnosis of peripheral artery occlusive disease (PAOD) which

is prevalent among patients on hemodialysis (HD).

Methods

This randomized trial aimed to evaluate the effect of far-infrared radiation (FIR) therapy on ABI in HD patients with PAOD. PAOD was defined as patients with ABI < 0.95. One hundred and eight HD patients were enrolled, including 50 in the control group and 58 in the FIR group. A WS TY101 FIR emitter was applied for 40 minutes during each HD session, three times per week for six months. The ABI was measured before and after the FIR therapy.

Results

Regardless of FIR therapy, the bilateral ABI decreased (in the FIR group, left: 0.88±0.22 to 0.85±0.24, p = 0.188; right: 0.92±0.20 to 0.90±0.23, p = 0.372; in control group, left: 0.91±0.23 to 0.88±0.21, p = 0144; right: 0.93±0.17 to 0.89±0.21, p = 0.082). Multivariate logistic analysis of the FIR group revealed that high uric acid (odds ratio [OR]: 2.335; 95% confidence interval [CI]: 1.117-4.882; p=0.024) and aspirin use (OR: 16.463; 95% CI: 1.787-151.638; p=0.013) were independently associated with increased bilateral ABI after FIR therapy.

Conclusions

This study demonstrates that ABI is not increased after FIR therapy in HD patients with PAOD. However, in the FIR group, patients with higher uric acid level or those who used aspirin have increased bilateral ABI after FIR therapy.

-Int. J. Med. Sci. 2016, 13(12): 970-976

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
More Posts